Clinical trial · Interventional
Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma
Intérêt de l'électroporation irréversible Dans le Traitement de l'adénocarcinome du pancréas
NCT03105921CI-TRIAL-00057453completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to evaluate the use of irreversible electroporation in the treatment of locally advanced cancers of the head of pancreas with vascular spread. This technique would allow to treat the unresectable part of the tumor to make it more accessible for a secondary surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Interventional Imaging | — | UNRESOLVED | — |
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NanoKnife | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Electrodes
- description
- Electrodes
- interventionNames
- Device: NanoKnife
Primary outcomes (1)
- measure
- R0 resection rate
- timeFrame
- 3 months
- description
- Assessment of the R0 resection (complete tumour removal with negative resection margins) rate of locally advanced pancreatic cancer treated by electroporation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically proven adenocarcinoma of the head of the pancreas (fine needle aspiration or biopsy) * Pancreatic adenocarcinoma locally advanced on imaging at diagnosis * Tumor of less than 7 cm in largest diameter * No chemotherapy or abdominal radiotherapy within five years before the inclusion in the study Exclusion Criteria: * Pancreatic adenocarcinoma of more than 7 cm of diameter or immediately operable on imaging data * Patient with contraindication of NanoKnife use * Patient with neurostimulator * Epileptic patient or with a myocardial infarction lasting less than 2 months * Presence of visceral or lymph node metastases or peritoneal carcinosis at the initial workup * Patient who cannot be treated with muscle blockers (curare) * Patient with a metallic stent or a medical device implanted near the area treated by electroporation
References
Publications (1)
- DERIVEDTasu JP, Herpe G, Damion J, Richer JP, Debeane B, Vionnet M, Rouleau L, Carretier M, Ferru A, Ingrand P, Tougeron D. Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study. Eur Radiol. 2024 Oct;34(10):6885-6895. doi: 10.1007/s00330-024-10613-x. Epub 2024 Mar 18. PMID 38494526